Asset profile
AZD8871
Unknown / undisclosed
Evidence outlook · program status
Discontinued (2020), for reasons the sponsor has not stated
AZD8871 (LAS191351) was AstraZeneca's inhaled dual M3-antagonist/beta2-agonist (MABA) for COPD and asthma, acquired with Almirall's respiratory franchise in 2014. AstraZeneca's FY2019 Form 20-F pipeline table still listed it in Phase II ('AZD8871 MABA COPD PP'); the FY2020 Form 20-F enumerates the respiratory portfolio and its discontinued projects (MEDI5117, Abediterol, AZD5634, Velsecorat) without any mention of AZD8871, dating the stop to 2020. No reason is given for AZD8871 specifically, and no divestment back to Almirall was found. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
43 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 43 same-indication; 24 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AZD8871: this drug | Phase 2 | — | Muscarinic receptors and beta-2 adrenergic receptors, Muscarinic receptors (M1-M3) and beta-2 adrenergic receptor | ||
| Aclidinium Bromide (Tudorza Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Benralizumab (Fasenra) | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophils | ||
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | ||
| Depemokimab | Approved | Monoclonal antibody | IL-5 | ||
| Ensifentrine (Ohtuvayre) | Approved | Small molecule | PDE3/PDE4 | ||
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Mepolizumab (Nucala) | Approved | Monoclonal antibody | IL-5, Interleukin-5 (IL-5), ligand-neutralizing | ||
| Olodaterol | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Olodaterol / Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Revefenacin (Yupelri) | Approved | Small molecule | Muscarinic receptors (antagonist) | ||
| Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | ||
| Umeclidinium (Incruse Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), M3 muscarinic acetylcholine receptor | ||
| Umeclidinium / Vilanterol | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor |
…and 28 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.